| Title: | Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs |
|---|
| Authors: | ID Morozova, Nataliia (Author)
ID Zajc Avramovič, Mojca (Author)
ID Markelj, Gašper (Author)
ID Toplak, Nataša (Author)
ID Avčin, Tadej (Author) |
|---|
| Files: |  PDF - Presentation file, download (966,01 KB)
MD5: 2D19D559F428C2EDCA38BD48C0857FDA
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Objective: To determine the dynamics of serum levels of TNF-α in patients with juvenile idiopathic arthritis (JIA) treated with anti-TNF-α biological drugs and investigate their association with the disease activity. Methods: We conducted a single-centre, observational cohort study in 98 patients with JIA (30 boys, 68 girls, mean age 11.3 years) treated with anti-TNF-α biological drugs. Clinical examinations and laboratory assessments of serum levels of TNF-α were performed before starting therapy with biological drug and at 6-month intervals afterwards up to 2.5 years. Results: The analysis of serum levels of TNF-α in relation to the disease activity states showed the highest mean serum levels of TNF-α in patients on etanercept who had low disease activity states and in patients on adalimumab who had inactive disease. The correlation analysis in patients with JIA treated with etanercept or adalimumab showed a weak negative correlation between the serum levels of TNF-α and JADAS10 scores (p = 0.007), (r = - 0.177). Conclusion: The assessment of serum levels of TNF-α in children with JIA during treatment with etanercept or adalimumab is not a reliable biomarker of disease activity or immunological remission. Longitudinal measurement of TNF-α has no added clinical value in patients with JIA treated with anti-TNF-α biological drugs. Key Points • There is limited evidence regarding the effect of anti-TNF therapy on serum concentrations of TNF-α in patients with juvenile idiopathic arthritis • Our study showed an increase in the serum level of TNF-α after the initiation of therapy with either etanercept or adalimumab, which was more significant in patients with inactive or low disease activity • Serum TNF-α is most likely not biologically active during therapy with TNF-α inhibitors and therefore not a reliable biomarker of disease activity or immunological remission in patients with juvenile idiopathic arthritis |
|---|
| Keywords: | adalimumab, cytokines, etanercept, juvenile idiopathic arthritis, tumour necrosis factor-alpha |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 2287-2293 |
|---|
| Numbering: | Vol. 43, iss. 7 |
|---|
| PID: | 20.500.12556/DiRROS-29784  |
|---|
| UDC: | 61 |
|---|
| ISSN on article: | 0770-3198 |
|---|
| DOI: | 10.1007/s10067-024-07012-4 |
|---|
| COBISS.SI-ID: | 203660291 |
|---|
| Note: |
|
|---|
| Publication date in DiRROS: | 05.06.2026 |
|---|
| Views: | 78 |
|---|
| Downloads: | 35 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
